leflunomide has been researched along with Anti-MuSK Myasthenia Gravis in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0." | 5.91 | Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. ( Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023) |
| "Leflunomide is an effective drug used in the treatment of rheumatoid arthritis." | 5.43 | Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. ( Chen, P; Deng, J; Feng, H; Liu, W; Luo, Y; Ou, C; Qiu, L, 2016) |
| "Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function." | 5.29 | Leflunomide prevents the development of experimentally induced myasthenia gravis. ( Apostolski, S; Bartlett, RR; Damjanovic, M; Isakovic, K; Kosec, D; Vidic-Dankovic, B, 1995) |
| "This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0." | 1.91 | Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. ( Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023) |
| "Leflunomide is an effective drug used in the treatment of rheumatoid arthritis." | 1.43 | Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. ( Chen, P; Deng, J; Feng, H; Liu, W; Luo, Y; Ou, C; Qiu, L, 2016) |
| "Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function." | 1.29 | Leflunomide prevents the development of experimentally induced myasthenia gravis. ( Apostolski, S; Bartlett, RR; Damjanovic, M; Isakovic, K; Kosec, D; Vidic-Dankovic, B, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X | 2 |
| Qiu, L | 3 |
| Lu, Y | 1 |
| Chen, J | 1 |
| Yang, W | 1 |
| Ou, C | 3 |
| Ran, H | 2 |
| Liu, W | 3 |
| Chen, P | 2 |
| Li, Y | 2 |
| Huang, H | 1 |
| Chen, Z | 1 |
| Liu, X | 1 |
| Huang, Z | 1 |
| Lin, Z | 1 |
| Feng, H | 1 |
| Deng, J | 1 |
| Luo, Y | 1 |
| Vidic-Dankovic, B | 1 |
| Kosec, D | 1 |
| Damjanovic, M | 1 |
| Apostolski, S | 1 |
| Isakovic, K | 1 |
| Bartlett, RR | 1 |
4 other studies available for leflunomide and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis.
Topics: Humans; Leflunomide; Myasthenia Gravis; Prednisone; Treatment Outcome | 2023 |
Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Cell Count; Child; Child, Preschool; Dendritic Cel | 2019 |
Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
Topics: Activities of Daily Living; Adolescent; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; | 2016 |
Leflunomide prevents the development of experimentally induced myasthenia gravis.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Female; Flow Cytometry; Immunization; Immunosuppressiv | 1995 |